New FDA deal keeps Gilead drug competitive with AstraZeneca and Daiichi in breast cancer treatment – MedCity News
The FDA has expanded approval of a targeted therapy from Gilead Sciences as a new first-line treatment for triple-negative breast ...
Read moreDetails
